Paltusotine is a small molecule commercialized by Crinetics Pharmaceuticals, with a leading Phase III program in Acromegaly. According to Globaldata, it is involved in 12 clinical trials, of which 7 were completed, 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Paltusotine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Paltusotine is expected to reach an annual total of $71 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Paltusotine Overview

Paltusotine hydrochloride (CRN-00808) is under development for the treatment of acromegaly and neuroendocrine tumors, carcinoid syndfrome. The drug candidate is administered through oral route. The drug candidate is a  biased nonpeptide acts by targeting somatostatin receptor. The drug candidate was under development for age-related macular degeneration (AMD) and diabetic retinopathy.

Crinetics Pharmaceuticals Overview

Crinetics Pharmaceuticals (Crinetics) is a pharmaceutical company. It developes of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products portfolio comprises paltusotine (Oral SST2 agonist); CRN04777 (SST5 agonist); and CRN04894 (ACTH agonist). It provides somatostatin agonists for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia. The company provides endocrine drug discovery and development through collaboration with healthcare and research institutes. Crinetics is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.1 million in FY2020. The operating loss of the company was US$107.7 million in FY2021, compared to an operating loss of US$75 million in FY2020. The net loss of the company was US$107.6 million in FY2021, compared to a net loss of US$73.8 million in FY2020. The company reported revenues of US$0.5 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.

For a complete picture of Paltusotine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.